Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Stock Performance

EW stock traded down $0.41 on Thursday, hitting $69.87. The company’s stock had a trading volume of 5,723,046 shares, compared to its average volume of 4,149,974. The stock has a market cap of $41.21 billion, a price-to-earnings ratio of 10.08, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The firm has a 50 day moving average of $71.91 and a two-hundred day moving average of $71.61. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the company posted $0.59 earnings per share. The business’s revenue was up 8.9% on a year-over-year basis. Equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on EW. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Robert W. Baird decreased their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a report on Friday, October 11th. Finally, Royal Bank of Canada upped their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $78.48.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. Oppenheimer Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 2.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 21,983 shares of the medical research company’s stock valued at $2,031,000 after acquiring an additional 615 shares in the last quarter. J.W. Cole Advisors Inc. lifted its position in Edwards Lifesciences by 7.4% in the second quarter. J.W. Cole Advisors Inc. now owns 2,956 shares of the medical research company’s stock valued at $273,000 after purchasing an additional 204 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Edwards Lifesciences by 18.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after purchasing an additional 219,486 shares in the last quarter. Edgestream Partners L.P. acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $438,000. Finally, Bradley Foster & Sargent Inc. CT raised its stake in shares of Edwards Lifesciences by 17.9% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 16,842 shares of the medical research company’s stock worth $1,556,000 after buying an additional 2,563 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.